Hartmut Goldschmidt

Research interests

Publications

• Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00466-6

• Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2024850

• Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2020.11.014

• Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

  The Lancet Haematology · 2019 · https://doi.org/10.1016/s2352-3026(19)30110-3

• International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30309-2

• Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

  The Lancet Haematology · 2019 · https://doi.org/10.1016/s2352-3026(19)30110-3

• Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1817249

• Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30152-4

• Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

  Blood · 2018 · https://doi.org/10.1182/blood-2018-03-840132

• A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

  Leukemia · 2018 · https://doi.org/10.1038/s41375-018-0196-8

• Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30189-4

• Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdx096

• Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

  Leukemia · 2017 · https://doi.org/10.1038/leu.2017.138

• Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

  Blood · 2016 · https://doi.org/10.1182/blood-2016-01-631200

• Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1607751

• International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30206-6

• Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)00464-7

• Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2015.61.2267

• Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2014.57.9961

• International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70442-5

• Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2013 · 10.1016/s1470-2045(13)70380-2

• IMWG consensus on risk stratification in multiple myeloma

  Leukemia · 2013 · https://doi.org/10.1038/leu.2013.247

• Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2011.39.6820

• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

  Leukemia · 2011 · https://doi.org/10.1038/leu.2011.196

• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

  Leukemia · 2011 · https://doi.org/10.1038/leu.2011.196

• Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2009.25.5356

• Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

  Blood · 2010 · https://doi.org/10.1182/blood-2009-12-261032

• Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

  New England Journal of Medicine · 2005 · https://doi.org/10.1056/nejmoa043445

Current projects

No projects listed.